Main menu


Reports: Pfizer and Moderna vaccines can train immune cells to target corona variants

Many variants of the Corona virus appeared and spread around the world, and were classified as variables of concern, and the delta variant, which was first discovered in India last October, is the “most transmissible” of all the variants identified so far. .

According to the World Health Organization (WHO), the United Nations health agency has confirmed that the delta variant has been detected in 96 countries and has become the dominant strain worldwide, and this has raised concerns about whether approved vaccines can protect us from the delta variant, and the good news is that Several vaccine makers, including Moderna and Pfizer, have claimed that their vaccines are highly effective against most common variants of concern.

Now, a new study conducted by researchers at the La Jolla Institute of Immunology (LJI) in California has found that Moderna and Pfizer's vaccines can stimulate T cells to fight coronavirus variants, and it includes data on 4 of the most prevalent volatile organic compounds: Alpha, beta, gamma.

The study has now been expanded to include a larger set of variables, including the delta variant (B.1.617.2), which became prevalent after the start of this study.

They found that both helper T cells and "killer" T cells from people who have recovered from the Corona virus or received the Moderna or Pfizer vaccines can still identify many variants related to the Corona virus, moreover, the study also indicates that the effect of the existing mutations In the variables of limited concern.

Several studies have linked variants of concern to lower levels of virus-fighting antibodies, but the new study shows that even if there is a decrease in the antibodies, the T cells remain largely unaffected and the two vaccines still work.

However, the Johnson & Johnson/Janssen COVID-19 vaccine was not included in the study because it was not available when the study began.

For the study, researchers analyzed T cells from people who had recovered from COVID-19, people who had received the Moderna or Pfizer-BioNTech vaccine, and people who had never been exposed to COVID-19. new variables.